Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer

Triple-negative breast cancer (TNBC) patients receive chemotherapy treatment, including doxorubicin, due to the lack of targeted therapies. Drug resistance is a major cause of treatment failure in TNBC and therefore, there is a need to identify biomarkers that determine effective drug response. A ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Velenosi, Thomas J., Krausz, Kristopher W., Hamada, Keisuke, Dorsey, Tiffany H., Ambs, Stefan, Takahashi, Shogo, Gonzalez, Frank J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547066/
https://www.ncbi.nlm.nih.gov/pubmed/36207498
http://dx.doi.org/10.1038/s41698-022-00313-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547066/
https://www.ncbi.nlm.nih.gov/pubmed/36207498
http://dx.doi.org/10.1038/s41698-022-00313-4

Ejemplares similares